Evidence map›Paper›PMID 33529490›Full record

ArticleThoracic cancer2021

Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.

Yunha Nam, Ho Cheol Kim, Young-Chul Kim, Seung Hun Jang, Kye Young Lee, Shin Yup Lee, Sang Hoon Lee, Sung Yong Lee, Seong Hoon Yoon, Jeong-Seon Ryu and 7 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 3 countries.

Yunha Nam *Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0003-3874-6089
Ho Cheol Kim *Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Young-Chul KimDepartment of Internal Medicine, Chonnam National University Medical School, and Chonnam National University Hwasun Hospital, Hwasun, South Korea.ORCID 0000-0001-7019-7687
Seung Hun JangDepartment of Pulmonary, Allergy and Critical Care Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea.
Kye Young LeeDepartment of Pulmonary Medicine, Konkuk University School of Medicine, Seoul, South Korea.
Shin Yup LeeDepartment of Internal Medicine, Kyungpook National University, School of Medicine, Daegu, South Korea.ORCID 0000-0002-2121-7335
Sang Hoon LeeDivision of Pulmonology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
Sung Yong LeeDivision of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea.
Seong Hoon YoonDepartment of Pulmonology and Allergy, Pusan National University Yangsan Hospital, Yangsan, South Korea.ORCID 0000-0002-2075-4702
Jeong-Seon RyuDepartment of Internal Medicine, Inha University Hospital, Incheon, South Korea.
Tae Won JangDepartment of Internal Medicine, Kosin University Medical College, Pusan, South Korea.
Yoon Soo ChangDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea.
Seung Joon KimDivision of Pulmonology, Department of Internal Medicine, The Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Chan Kwon ParkDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
Jeong Eun LeeDivision of Pulmonology, Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, South Korea.ORCID 0000-0001-6173-2748
Chi Young JungDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, South Korea.
Chang-Min ChoiDepartment of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0002-2881-4669
Ulsan College · KRSeverance Hospital · KRYonsei University · KRCatholic University of Korea · KRChonnam National University Hwasun Hospital · KRChungnam National University · KRDaegu Catholic University Medical Center · KRInha University Hospital · KRKonkuk University · KRKosin University · KRPusan National University Yangsan Hospital · KRSacred Heart Hospital · IEThe Catholic University of Korea Yeouido St. Mary's Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn this study, we investigated the risk factors of acquired T790M mutation among patients with lung adenocarcinoma with epidermal growth factor receptor (EGFR) tyrosine mutation who were treated with EGFR-tyrosine kinase inhibitors (TKIs). The aim was to identify the clinical impact of rebiopsy.

methodsThis multicenter, retrospective cohort study was conducted in South Korea from January 2007 to June 2017. Patients with adenocarcinoma with EGFR mutation who underwent rebiopsy and were treated with EGFR-TKIs were included.

resultsOf a total of 352 patients, T790M mutation was identified in 156 (41.9%) at the time of rebiopsy. The median duration from initial biopsy to rebiopsy was 17 months. Univariate logistic regression analysis revealed associations of exon 19 deletion (odds ratio [OR], 1.643; p = 0.026), absence of L858R (OR, 0.627; p = 0.042), and previous EGFR-TKI treatment duration (OR, 1.039; p < 0.001) with T790M mutation. Previous EGFR-TKI treatment duration (OR, 3.580; p < 0.001) was independently associated with T790M mutation. A multivariate Cox proportional hazard model revealed that brain metastasis at initial diagnosis (hazard ratio, 1.390; p = 0.050) tended to be associated with T790M mutation. Among the patients with T790M mutation at rebiopsy, the osimertinib user group (n = 90) had a better one-year survival (68.7 vs. 58.3%, p = 0.048) than the osimertinib nonuser group (n = 66).

conclusionsRebiopsy might affect the clinical course of patients with EGFR-mutant adenocarcinoma who receive EGFR-TKIs.

Indexed as

Adenocarcinoma of LungAgedBiopsyErbB ReceptorsFemaleHumansLung NeoplasmsMaleMiddle AgedMutationRetrospective StudiesEGFR protein, humanErbB Receptorsacquired resistanceEGFR-TKIlung cancerrebiopsyT790M

Identifiers

PMID33529490
PMCPMC7952806
OpenAlexW3127965499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.